[{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Vpx Lentiviral Vector","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ CARISMA Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Carisma Therapeutics \/ CARISMA Therapeutics"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Symbiosis II","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"CT-0508","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Carisma Therapeutics \/ Symbiosis II","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Symbiosis II"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Cevec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"CAR-macrophage immunotherapies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Carisma Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Carisma Therapeutics \/ Carisma Therapeutics"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"IP Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"CT-0508","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"Carisma Therapeutics \/ IP Group","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ IP Group"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"CT-0508","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ CARISMA Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ CARISMA Therapeutics"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"In-vivo Engineered CAR Monocyte Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Carisma Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Moderna","highestDevelopmentStatusID":"2","companyTruncated":"Carisma Therapeutics \/ Moderna"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"CT-0508","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Carisma Therapeutics \/ Novartis","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Novartis"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CT-0508","moa":"T Cell checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Carisma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CT-0508","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carisma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Sesen Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"CT-0508","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Sesen Bio","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Sesen Bio"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CT-0508","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carisma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Sesen Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Merger","leadProduct":"Oportuzumab Monatox","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Carisma Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Carisma Therapeutics \/ Sesen Bio","highestDevelopmentStatusID":"10","companyTruncated":"Carisma Therapeutics \/ Sesen Bio"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Sesen Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"CT-0508","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Carisma Therapeutics \/ Carisma Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Carisma Therapeutics"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"CT-0508","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"CAR-M-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Carisma Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"CT-0525","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Carisma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CT-0525","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carisma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CAR-M-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Carisma Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CT-0525","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Expanded Collaboration","leadProduct":"CAR-M-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Carisma Therapeutics \/ Moderna Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Carisma Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Under this expanded collaboration,Carisma and Moderna will leverage Carisma's CAR-M technology and Moderna's mRNA/LNP platform to develop novel approaches for the treatment of autoimmune disease.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 10, 2024

                          Lead Product(s) : CAR-M-based Therapy

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery Platform

                          Sponsor : Moderna Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Carisma collaboration with Moderna announces the development candidate is an in vivo CAR-M targeting Glypican-3 and is designed to treat solid tumors, including hepatocellular carcinoma.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 27, 2024

                          Lead Product(s) : CAR-M-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Moderna Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : CT-0525 is an ex vivo gene-modified autologous CAR-Monocyte cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2).

                          Brand Name : CT-0525

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          June 25, 2024

                          Lead Product(s) : CT-0525

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : CT-0525 is an ex vivo gene-modified autologous CAR-monocyte cellular therapy, which is being evaluated for the treatment of patients with solid tumors that overexpress HER2.

                          Brand Name : CT-0525

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 16, 2024

                          Lead Product(s) : CT-0525

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The collaboration brings together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's messenger RNA (mRNA) and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics for oncology.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 14, 2023

                          Lead Product(s) : CAR-M-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Moderna Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : CT-0525 is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2).

                          Brand Name : CT-0525

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          November 28, 2023

                          Lead Product(s) : CT-0525

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : CT-0508 is a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). It is being evaluated in a landmark Phase 1 multi-center clinical trial that focuses on patients with recurrent or metastatic HER2-overexp...

                          Brand Name : CT-0508

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          June 28, 2023

                          Lead Product(s) : CT-0508,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Merck & Co

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The combined company will develop Carisma's lead candidate CT-0508, a CAR-M cell therapy and will also accelerate the growth of company's platform and pipeline within and outside of oncology.

                          Brand Name : CT-0508

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 21, 2023

                          Lead Product(s) : CT-0508,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Sesen Bio

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          09

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Vicineum (oportuzumab monatox) is an investigational locally administered recombinant fusion protein that targets epithelial cell adhesion molecule antigens on the surface of tumor cells to deliver Pseudomonas Exotoxin A.

                          Brand Name : Vicineum

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 29, 2022

                          Lead Product(s) : Oportuzumab Monatox

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Sesen Bio

                          Deal Size : $30.0 million

                          Deal Type : Merger

                          blank

                          10

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Carisma is developing CT-0508 to target HER2-positive solid tumors. While its expression in normal tissues is low, HER2 is highly expressed in a wide range of solid tumors and plays an active role in both malignant transformation and tumor.

                          Brand Name : CT-0508

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          November 01, 2022

                          Lead Product(s) : CT-0508

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank